GEMAC – History
Small endogenous molecules (vitamins, amino acids, fatty acids, neurotransmitters) are essential for the understanding of the pathogenic processes of the human body.
Dr Geffard’s team was the first to discover the role of acetylcholine in the pathogenesis of myasthenia.
Further studies focused on the Central Nervous System mechanism. This approach enabled an in-depth comprehension of various pathologies including chronic degenerative diseases.
When GEMAC was founded in 2001, all work of Dr Geffard’s team was incorporated in the company, like patents, experimental works, preclinical data, etc.
Some keys scientists were also recruited by the company, strengthening the company know-how and potential ouput.
Gemac is now engaged in the clinical developement of its proprietary molecules.